ORKA (Oruka Therapeutics) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Oruka Therapeutics's Revenue for the six months ended in Dec. 2024 was $0.00 Mil. Oruka Therapeutics's average Accounts Receivable for the six months ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics Receivables Turnover Historical Data

The historical data trend for Oruka Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Receivables Turnover Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Receivables Turnover

Oruka Therapeutics Semi-Annual Data
	Dec24
Receivables Turnover	-

Competitive Comparison of Oruka Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Oruka Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Oruka Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0	/ (	(	+	0)	/	1 )
=	0	/	0
=	N/A

Oruka Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: . 20 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(	+	0)	/	1 )
=	0	/	0
=	N/A

Oruka Therapeutics (NAS:ORKA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Oruka Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.